The Next Step in the Treatment of Stroke.

In the URICO-ICTUS trial, a multicenter, randomized, double blind, phase 2b/3 trial, patients that received uric acid in combination with alteplase (<4.5 h) did not improve outcomes at 90 days, but in a sensitivity analyses, a borderline significance was seen in patients with uric acid treatment who experienced an ordinal shift in mRS, decreasing their residual disability by a median of 1 point on the mRS compared to the placebo group ( 107 ).

also in 7,017 other papers

The ESCAPE-NA1 trial failed to achieve significance in its primary outcome for the overall study population most likely due to proteolysis of nerinetide by the plasmin generated by alteplase.

also in 299 other papers